Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Andrei Iagaru
With
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Primary Objective:
1. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can detect additional cancers over mpMRI.
2. To demonstrate that 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI can assess changes in response to treatment and predict progression free survival (PFS) at 24 months.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients must be at least 18 years of age;
Patients must be able to provide informed consent;
Histologically proven low-grade or intermediate-grade prostate cancer (PC)
Scheduled to undergo targeted local therapy (HDR brachytherapy).
You may not be if
Inability to lie still for the entire imaging time;
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.);
Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance;
Metallic implants (contraindicated for MRI).
Clareo Health | HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
